Your search for non small cell lung cancer returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Diana Ernst, RPh remove

Your search for non small cell lung cancer returned 17 results

Sort Results:

Relevant Recent
News

Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
News

Antibiotic Use May Impact PFS, Overall Survival in Lung Cancer Patients Treated With Pembrolizumab

In patients with naïve advanced non-small cell lung cancer (NSCLC) and high PD-LI expression who are treated with pembrolizumab, the use of intravenous (IV) antibiotics may negatively impact progression free survival (PFS) and overall survival, according to research presented at the IASLC 2019 World Conference on Lung Cancer. To evaluate the effect of antibiotics on…
News

Keytruda Wins Approval for Advanced Esophageal Cancer

The FDA approved Keytruda for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test
News

Cyramza Approved to Treat Hepatocellular Carcinoma

The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.